News
Novo Nordisk cuts forecasts as Ozempic and Wegovy sales hit by US copycat versions
Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight-loss drug Wegovy, as unauthorised compounded versions of its GLP-1 drugs eat into sales — particularly in the United States,
Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the ...
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...
Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...
5h
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.
Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback